Elad Sharon: Two of my major trials led to FDA Oncology approvals

Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared on X/Twitter:

“Past week, two of my major trials while I was at NCI CTEP Clinical Research led to FDA Oncology approvals… lots of effort from Amgen/ECOG-ACRIN Cancer Research Group team for E1910 and
Merck/NRG Oncology team for NRGgy018. Exciting to see these efforts come through for our patients!”

Source: Elad Sharon/X